These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 9425944)

  • 1. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.
    Maruyama T; Kuwata S; Koike K; Iino S; Yasuda K; Yotsuyanagi H; Moriya K; Maekawa H; Yamada H; Shibata Y; Milich DR
    Hepatology; 1998 Jan; 27(1):245-53. PubMed ID: 9425944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region.
    Maruyama T; Mitsui H; Maekawa H; Yamada H; Hirayama M; Iino S; Yasuda K; Koike K; Kimura S; Milich DR
    Am J Gastroenterol; 2000 Oct; 95(10):2894-904. PubMed ID: 11051365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B.
    Loriot MA; Marcellin P; Talbodec N; Guigonis V; Gigou M; Boyer N; Bezeaud A; Erlinger S; Benhamou JP
    Hepatology; 1995 Mar; 21(3):627-31. PubMed ID: 7875659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B.
    Liu CJ; Chen PJ; Lai MY; Lin FY; Wang T; Kao JH; Chen DS
    Liver Int; 2006 Oct; 26(8):949-55. PubMed ID: 16953835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
    Kim HJ; Yoo BC
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter.
    Yamaura T; Tanaka E; Matsumoto A; Rokuhara A; Orii K; Yoshizawa K; Miyakawa Y; Kiyosawa K
    J Med Virol; 2003 Aug; 70(4):545-52. PubMed ID: 12794716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
    Ferns RB; Naoumov NV; Gilson RJ; Tedder RS
    J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of precore mutants in anti-hepatitis B e antigen positive subjects with chronic hepatitis B virus infection in Chennai, Southern India.
    Shanmugam S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Shankar EM; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
    J Microbiol Biotechnol; 2008 Oct; 18(10):1722-8. PubMed ID: 18955826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels.
    Cabrerizo M; Bartolomé J; Iñigo ER; López-Alcorocho JM; Cotonat T; Carreño V
    J Med Virol; 1998 Dec; 56(4):294-9. PubMed ID: 9829632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
    Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
    Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany.
    Knöll A; Rohrhofer A; Kochanowski B; Wurm EM; Jilg W
    J Med Virol; 1999 Sep; 59(1):14-8. PubMed ID: 10440802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.
    Chan HL; Tsang SW; Liew CT; Tse CH; Wong ML; Ching JY; Leung NW; Tam JS; Sung JJ
    Am J Gastroenterol; 2002 Feb; 97(2):406-12. PubMed ID: 11866280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.
    Manesis EK; Papatheodoridis GV; Sevastianos V; Cholongitas E; Papaioannou C; Hadziyannis SJ
    Am J Gastroenterol; 2003 Oct; 98(10):2261-7. PubMed ID: 14572577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
    Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
    J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
    Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
    Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
    Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.